Genome-wide Association Study Using Pooled DNA to Identify Candidate Markers Mediating Susceptibility to Postoperative Nausea and Vomiting

Janicki, Piotr K.; Vealey, Ryan J.; Liu, Jiabin; Escajeda, Jeremiah; Postuła, Marek; Welker, Kelli

doi:10.1097/aln.0b013e31821810c7

Cited by 99 publications

(82 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the researchers found that intractable PONV ran in families. 21 In addition, this study confirmed an association between a single nucleotide polymorphism and PONV susceptibility.…”

Section: Patient-specific Risk Factorssupporting

confidence: 69%

See 1 more Smart Citation

Clinical utility of antiemetics and complementary therapies in the prevention of postoperative nausea and vomiting

Collins¹

2013

View full text Add to dashboard Cite

Postoperative nausea and vomiting (PONV) is a persistent problem in perianesthesia practice. Approximately 30% of patients receiving anesthesia will experience this complication, which can increase patient dissatisfaction, increase costs, and in some patients precipitate other postoperative complications. During the last three decades, there has been increasing interest and research on best practices to diminish the incidence of this clinical problem, as patient satisfaction is linked to PONV guideline use. Some institutions have low incident rates because of consistent protocol use, and new medication classifications and multiple complementary therapies have been incorporated into daily use. There are several clinically useful guidelines and algorithms used to guide primary prevention strategies, as discussed in this review. However, severe PONV continues to be refractory to available interventions, and the best hope for elimination of this complication may arise from pharmacogenomics.

show abstract

Section: Patient-specific Risk Factorssupporting

confidence: 69%

“…21 As receptor sites are important in drug metabolism, and these sites are genetically determined, several studies have been conducted during the last decade. This author identified genetic studies that have been undertaken by seven additional researchers specific to a particular medication's effect and the genetic variations of a receptor.…”

Section: Geneticsmentioning

confidence: 99%

Clinical utility of antiemetics and complementary therapies in the prevention of postoperative nausea and vomiting

Collins¹

2013

View full text Add to dashboard Cite

show abstract

“…Individual differences in the sensitivity to, and metabolism of, antiemetic drugs were reported previously [23]. Recent reports have shown that genetic polymorphisms of several known genes, in several metabolic pathways, were associated with CINV [2,24].…”

mentioning

confidence: 92%

Pharmacogenetics of Chemotherapy-Induced Nausea and Vomiting

Sugino

Janicki

2015

Pharmacogenomics

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.

show abstract

“…Studies have demonstrated associations between PONV and specific genetic polymorphisms, such as specific single nucleotide traits of acetylcholine M3 subtype receptors (linked to motion sickness) as well cytochrome P450 genotypes 5 responsible for rapid metabolism of many drugs and toxins. 6 These could act as valuable targets in the future for patient specific pharmacogenetic targets.…”

Section: Patient Factorsmentioning

confidence: 99%

Postoperative nausea and vomiting

Blackburn¹,

Spencer²

2015

Anaesthesia & Intensive Care Medicine

View full text Add to dashboard Cite

Postoperative nausea and vomiting (PONV) remains a common clinical problem that increases patient morbidity, healthcare costs and affects patient satisfaction. This article outlines the physiology, reviews the available drugs and suggests a structure using risk stratification that helps to plan sensible clinical management.Postoperative nausea and vomiting (PONV) has an incidence of up to 30% 1,2 and is one of the most feared side effects of anaesthesia, even above pain. 3 Although in most cases it is self-limiting, each episode of vomiting delays discharge from the recovery room, increases the risk of unplanned admission and may be associated with more severe complications including pulmonary aspiration, dehydration, electrolyte abnormalities, raised intra-cranial and intraocular pressures, wound dehiscence and oesophageal rupture.The management of PONV involves risk stratification, prevention and treatment. This can utilize both pharmacological and non-pharmacological interventions. DefinitionsNausea is the sensation of needing to vomit, which may include activation of central, sympathetic and parasympathetic responses.Vomiting is the involuntary oral expulsion of gastric contents via coordinated autonomic, gastrointestinal and respiratory system activity. It can be considered in two phases. In the pre-ejection phase, sympathetic activation causes tachypnoea, tachycardia, hypertension, diaphoresis, pallor and hypersalivation. During the ejection phase, the epiglottis closes and forceful coordination of diaphragm, abdominal musculature and oesophagogastric constrictors leads to forceful expulsion of gastric and upper duodenal contents. Pathophysiology of nausea and vomitingThe physiology of nausea and vomiting is complex and new pathways remain to be discovered. A good understanding of current knowledge helps explain the pharmacological targets and therapies detailed below. Two key areas of the brain are important in the action of vomiting: the vomiting centre and the chemoreceptor trigger zone (CTZ) (Figure 1). The vomiting center (VC)This lies in the lateral reticular formation of the medulla and receives afferent impulses via cranial nerves (CN) from the vestibulocochlear apparatus of the middle ear (CN VIII), carotid baroreceptor impulses (CN IX), gastrointestinal chemo-and stretch receptors (CN X) and aortic baroreceptors (CN X). It also receives afferents from higher cortical centres involved in pain, anticipation, memory, sight and fear as well as spinal cord afferents from peripheral pain pathways.The VC coordinates actions of the smooth and striated muscles involved in vomiting via the 'special visceral efferent nerves', CN V, VII, IX, X and XI. These innervate the muscles of the face, neck and oropharynx in a coordinated fashion. Motor, sympathetic and parasympathetic outflow to the gastrointestinal tract and secretory organs are carried by the autonomic general visceral efferents of CN II, VII, IX and X. Finally efferent branches from the VC travel via spinal nerves to the diaphragm and abdominal musc...

show abstract

Genome-wide Association Study Using Pooled DNA to Identify Candidate Markers Mediating Susceptibility to Postoperative Nausea and Vomiting

Cited by 99 publications

References 37 publications

Clinical utility of antiemetics and complementary therapies in the prevention of postoperative nausea and vomiting

Clinical utility of antiemetics and complementary therapies in the prevention of postoperative nausea and vomiting

Pharmacogenetics of Chemotherapy-Induced Nausea and Vomiting

Postoperative nausea and vomiting

Contact Info

Product

Resources

About